Tesamorelin

Tesamorelin is a synthetic GHRH analog, stabilized with a trans-3-hexenoic acid group that lets it outlast the body's own GHRH(1-44). It binds pituitary GHRH receptors and prompts the gland to release its own GH in pulses, which then lifts IGF-1. The point worth holding onto: it works through the natural pituitary–GH–IGF-1 axis rather than overriding it. The downstream result that earned approval is a measurable drop in visceral fat, studied most thoroughly in HIV-associated lipodystrophy.

This is the strongest evidence profile on the whole site, and it is not close. Two large double-blind, placebo-controlled phase 3 RCTs, a pooled analysis, and safety-extension data — all in HIV-infected adults with lipodystrophy. The pooled analysis (Falutz et al., 2010, JCEM) showed a statistically significant reduction in trunk fat, measured by CT, versus placebo over 26 weeks; the longer data, 52 weeks with extension, held the benefit at acceptable safety. Here is the boundary that matters: every one of those trials is in the HIV lipodystrophy population. Stretching the results to healthy adults or physique enhancement is not something the data supports, however reasonable it sounds.

• Significant visceral-fat reduction in HIV-associated lipodystrophy (phase 3 RCTs)
• Higher GH and IGF-1 versus placebo in HIV patients
• Modest favorable lipid changes tied to the visceral-fat reduction
• Effect sustained across 52 weeks in the long-term safety extension

• FDA approval is narrow: HIV-associated lipodystrophy only — use in other populations is off-label and evidence-free
• Can cause fluid retention, arthralgia, myalgia, and peripheral edema
• Raises IGF-1; potential concern in individuals with active malignancy (not studied in cancer patients)
• Injection-site reactions are common
• Not approved for body-composition improvement in healthy or non-HIV populations; off-label use lacks RCT support
• Elevated glucose possible; monitor in patients at risk for diabetes

FDA-approved. Approved by the FDA for one or more human indications.

Goals studied: Visceral fat reduction, Body composition, GH / IGF-1 support

What is tesamorelin approved for?

In the US, tesamorelin (Egrifta / Egrifta SV) is FDA-approved specifically for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. It is not approved for general fat loss or anti-aging in healthy individuals.

How does tesamorelin differ from sermorelin or CJC-1295?

Tesamorelin is chemically modified for stability and has been through rigorous RCT testing with FDA approval. Sermorelin and CJC-1295 are also GHRH analogs but have weaker human evidence and operate through the same basic receptor pathway.

Can tesamorelin be used for body composition in people without HIV?

Off-label use exists, but there are no published RCTs supporting its use in non-HIV populations for body composition. Extrapolating HIV-lipodystrophy trial data to healthy adults is not scientifically justified.

1. [1]
   Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data

   Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S · The Journal of Clinical Endocrinology and Metabolism · 2010 · PMID 20554713 · model: human

   Pooled analysis of two phase 3 RCTs showing tesamorelin significantly reduced visceral adipose tissue vs. placebo over 26 weeks in HIV-infected adults with lipodystrophy.

2. [2]
   Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation

   Falutz J, Allas S, Mamputu JC, Potvin D, Kotler D, Somero M, Berger D, Brown S, Richmond G, Fessel J, Turner R, Grinspoon S · AIDS · 2008 · PMID 18690162 · model: human

   Safety extension data over 52 weeks showing sustained visceral fat reduction and a tolerability profile consistent with the phase 3 trial period.

3. [3]
   Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin

   Stanley TL, Falutz J, Mamputu JC, Soulban G, Potvin D, Grinspoon SK · Clinical Infectious Diseases · 2012 · PMID 22495074 · model: human

   Secondary analysis of phase 3 data linking tesamorelin-induced visceral fat reduction to improvements in triglycerides and other cardiometabolic markers.